We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice.
- Authors
Casanova-Martínez, Cristina; Romero-Ventosa, Elena Yaiza; González-Costas, Sonia; Arroyo-Conde, Cecilia; Piñeiro-Corrales, Guadalupe; Casanova-Martinez, Cristina
- Abstract
<bold>Context: </bold>Pancreatic cancer in a common tumor in our country for which there are various treatment alternatives.<bold>Objective: </bold>Evaluate the effectiveness and safety of nab-paclitaxel and gemcitabine in everyday clinical practice.<bold>Settings and Design: </bold>Observational, retrospective study at a tertiary university hospital.<bold>Subjects and Methods: </bold>We included patients diagnosed of metastatic or locally advanced pancreatic cancer that were being treated with nab-paclitaxel and gemcitabine. We recorded response, progression-free survival (PFS), and overall survival (OS) rates together with toxicities.<bold>Statistical Analysis Used: </bold>We used SPSS program for Windows. We conducted descriptive statistics using averages, medians, standard deviations or ranges, and percentages.<bold>Results: </bold>We included 15 patients. At 3 months, there were no complete responses; 20% showed partial responses, and in 60% of patients, the disease stabilized. The median PFS was 8.9 months and the OS was 9.6. The most important adverse reactions were neutropenia, fatigue, and nausea/vomiting.<bold>Conclusions: </bold>The treatment regimen leads to increased survival in these patients with an acceptable toxicity profile.
- Subjects
PACLITAXEL; PANCREATIC cancer; CANCER treatment; CANCER chemotherapy; ANTINEOPLASTIC agents
- Publication
Journal of Cancer Research & Therapeutics, 2018, Vol 14, pS730
- ISSN
0973-1482
- Publication type
journal article
- DOI
10.4103/0973-1482.188292